Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Epigenomics ; 11(10): 1209-1231, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-31339046

RESUMEN

Aim: This study aimed to excavate the roles of BCYRN1 in hepatocellular carcinoma (HCC). Methods: A comprehensive strategy of microarray data mining, computational biology and experimental verification were adopted to assess the clinical significance of BCYRN1 and identify related pathways. Results:BCYRN1 was upregulated in HCC and its expression was positively associated with both tumor, node, metastasis and worse survival rate in patients with HCC. Through combing plasma BCYRN1 with alpha fetoprotein, the diagnosis of HCC was remarkably improved. BCYRN1 may regulate some cancer-related pathways to promote HCC initiation via an lncRNA-miRNA-mRNA network. Conclusion: Our results propose BCYRN1 as a potential diagnostic and prognostic biomarker and offer a novel perspective to explore the etiopathogenesis of HCC.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Carcinoma Hepatocelular/patología , Regulación Neoplásica de la Expresión Génica , Neoplasias Hepáticas/patología , MicroARNs/metabolismo , ARN Largo no Codificante/metabolismo , ARN Mensajero/metabolismo , Biomarcadores de Tumor/genética , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/metabolismo , Biología Computacional , Femenino , Estudios de Seguimiento , Redes Reguladoras de Genes , Humanos , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/metabolismo , Masculino , MicroARNs/genética , Persona de Mediana Edad , Pronóstico , Mapas de Interacción de Proteínas , ARN Largo no Codificante/genética , ARN Mensajero/genética , Tasa de Supervivencia , Transcriptoma , alfa-Fetoproteínas/genética , alfa-Fetoproteínas/metabolismo
2.
Technol Cancer Res Treat ; 18: 1533033819846632, 2019 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-31106685

RESUMEN

α-Fetoprotein is commonly used in the diagnosis of hepatocellular carcinoma. However, the diagnostic significance of α-fetoprotein has been questioned because a number of patients with hepatocellular carcinoma are α-fetoprotein negative. It is therefore necessary to develop novel noninvasive techniques for the early diagnosis of hepatocellular carcinoma, particularly when α-fetoprotein level is low or negative. The current study aimed to evaluate the diagnostic efficiency of hematological parameters to determine which can act as surrogate markers in α-fetoprotein-negative hepatocellular carcinoma. Therefore, a retrospective study was conducted on a training set recruited from Zhongnan Hospital of Wuhan University-including 171 α-fetoprotein-negative patients with hepatocellular carcinoma and 102 healthy individuals. The results show that mean values of mean platelet volume, red blood cell distribution width, mean platelet volume-PC ratio, neutrophils-lymphocytes ratio, and platelet count-lymphocytes ratio were significantly higher in patients with hepatocellular carcinoma in comparison to the healthy individuals. Most of these parameters showed moderate area under the curve in α-fetoprotein-negative patients with hepatocellular carcinoma, but their sensitivities or specificities were not satisfactory enough. So, we built a logistic regression model combining multiple hematological parameters. This model presented better diagnostic efficiency with area under the curve of 0.922, sensitivity of 83.0%, and specificity of 93.1%. In addition, the 4 validation sets from different hospitals were used to validate the model. They all showed good area under the curve with satisfactory sensitivities or specificities. These data indicate that the logistic regression model combining multiple hematological parameters has better diagnostic efficiency, and they might be helpful for the early diagnosis for α-fetoprotein-negative hepatocellular carcinoma.


Asunto(s)
Carcinoma Hepatocelular/diagnóstico , Neoplasias Hepáticas/diagnóstico , Modelos Logísticos , Algoritmos , Biomarcadores de Tumor , Carcinoma Hepatocelular/metabolismo , Femenino , Humanos , Neoplasias Hepáticas/metabolismo , Masculino , Estadificación de Neoplasias , Pronóstico , Curva ROC , Reproducibilidad de los Resultados , Estudios Retrospectivos , Flujo de Trabajo , alfa-Fetoproteínas/metabolismo
3.
Anal Cell Pathol (Amst) ; 2019: 9740475, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31934534

RESUMEN

Colorectal cancer (CRC) is one of the most frequent cancers occurring in developed countries. Distant CRC metastasis causes more than 90% of CRC-associated mortality. MicroRNAs (miRNAs) play a key role in regulating tumor metastasis and could be potential diagnostic biomarkers in CRC patients. This study is aimed at identifying miRNAs that can be used as diagnostic biomarkers for CRC metastasis. Towards this goal, we compared the expression of five miRNAs commonly associated with metastasis (i.e., miR-10b, miR-200c, miR-155, miR-21, and miR-31) between primary CRC (pCRC) tissues and corresponding metastatic lymph nodes (mCRC). Further, bioinformatics analysis of miR-31 was performed to predict target genes and related signaling pathways. Results showed that miR-31, miR-21, miR-10b, and miR-155 expression was increased to different extents, while miR-200c expression was lower in mCRC than that in pCRC. Moreover, we found that the level of both miR-31 and miR-21 was notably increased in pCRC when lymph node metastasis (LNM) was present, and the increase of miR-31 expression was more profound. Hence, upregulated miR-31 and miR-21 expression might be a miRNA signature in CRC metastasis. Moreover, we detected a higher miR-31 level in the plasma of CRC patients with LNM compared to patients without LNM or healthy individuals. With the bioinformatics analysis of miR-31, 121 putative target genes and transition of mitotic cell cycle and Wnt signaling pathway were identified to possibly play a role in CRC progression. We next identified seven hub genes via module analysis; of these, TNS1 was most likely to be the target of miR-31 and had significant prognostic value for CRC patients. In conclusion, miR-31 is significantly increased in the cancer tissues and plasma of CRC patients with LNM; thus, a high level of miR-31 in the plasma is a potential biomarker for the diagnosis of LNM of CRC.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Neoplasias Colorrectales/metabolismo , Metástasis Linfática/diagnóstico , MicroARNs/sangre , Biomarcadores de Tumor/genética , Neoplasias Colorrectales/genética , Neoplasias Colorrectales/mortalidad , Neoplasias Colorrectales/patología , Biología Computacional , Regulación Neoplásica de la Expresión Génica/genética , Ontología de Genes , Humanos , Estimación de Kaplan-Meier , Metástasis Linfática/genética , Metástasis Linfática/patología , MicroARNs/genética , MicroARNs/metabolismo , Familia de Multigenes , Estadificación de Neoplasias , Pronóstico , Mapas de Interacción de Proteínas , Regulación hacia Arriba , Vía de Señalización Wnt/genética
4.
Front Oncol ; 8: 569, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30560088

RESUMEN

Objective: To investigate the potential biomarkers for venous metastasis of hepatocellular carcinoma (HCC), and briefly discuss their target genes and the signaling pathways they are involved in. Materials and Method: The dataset GSE6857 was downloaded from GEO. Significantly differentially expressed miRNAs were identified using the R package "limma," After that, the survival analysis was conducted to discover the significance of these up-regulated miRNAs for the prognosis of HCC patients. Additionally, miRNAs which were up-regulated in venous metastasis positive HCC tissues and were significant for the prognosis of HCC patients were further verified in clinical samples using RT-qPCR. The miRNAs were then analyzed for their correlations with clinical characteristics including survival time, AFP level, pathological grade, TNM stage, tumor stage, lymph-node metastasis, distant metastasis, child-pugh score, vascular invasion, liver fibrosis and race using 375 HCC samples downloaded from the TCGA database. The target genes of these miRNAs were obtained using a miRNA target gene prediction database, and their functions were analyzed using the online tool DAVID. Results: 15 miRNAs were differentially expressed in samples with venous metastasis, among which 7 were up-regulated in venous metastasis positive HCC samples. As one of the up-regulated miRNAs, hsa-miR-210 was identified as an independent prognostic factor for HCC. Using RT-qPCR, it was evident that hsa-miR-210 expression was significantly higher in venous metastasis positive HCC samples (p = 0.0036). Further analysis indicated that hsa-miR-210 was positively associated with AFP level, pathological grade, TNM stage, tumor stage and vascular invasion. A total of 168 hsa-miR-210 target genes, which are mainly related to tumor metastasis and tumor signaling pathways, were also predicted in this study. Conclusion: hsa-miR-210 might promote vascular invasion of HCC cells and could be used as a prognostic biomarker.

5.
J Cancer ; 9(19): 3435-3446, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30310500

RESUMEN

Background: miRNAs dysregulate in hepatocellular carcinoma (HCC), showing promise for diagnostic biomarkers which may be found through exploration of differentially expressed miRNAs when comparing HCC and normal liver tissues. Materials and Methods: In the present research, candidate miRNAs were selected and verified using screening dataset GSE12717 and training dataset GSE10694, respectively. A miRNA combination was constructed using stepwise logistic regression analysis and validated using two datasets GSE74618 and TCGA. Target genes of miRNAs in the combination were obtained using a miRNA target gene prediction database. Functional analysis was conducted using an online tool DAVID. We also analyzed the mRNA-Seq data of project LIHC from TCGA to identify the hub target genes of the miRNAs. Results: A miRNA combination, which is composed of hsa-miR-221 and hsa-miR-29c was defined in this study. The miRNA combination is more effective in discriminating HCC patients from normal individuals than individual miRNAs. Additionally, the combined miRNAs showed a lower misdiagnosis rate than AFP in HCC diagnosis. In terms of the functional analysis, a total of 27 target genes of hsa-miR-221 and 96 target genes of hsa-miR-29c were obtained. Among which, INSIG1 was the common target of the two miRNAs. It was also found that both previously mentioned miRNAs played important roles in the regulation of transcription, cell proliferation, and involvement in cancer-related pathways. Lastly, 2 hub target genes of hsa-miR-221 and 16 hub target genes of hsa-miR-29c were obtained. Conclusion: We established a miRNA combination as a promising tool for HCC diagnosis, and the target genes we predicted provide possible points of penetration for researching these two miRNAs in HCC.

6.
Cancer Manag Res ; 10: 1449-1459, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29922089

RESUMEN

BACKGROUND: Tissue biopsy-based cancer diagnosis has limitations because of the fact that tumor tissues are in constant evolution and extremely heterogeneous. The current study was aimed to examine whether tumor-educated blood platelets (TEPs) might be a potential all-in-one source for blood-based cancer diagnostics to overcome the limitations of conventional cancer biopsy. METHODS: In the present study, we evaluated the expression pattern of MAGI2 antisense RNA 3 (MAGI2-AS3) and ZNFX1 antisense RNA 1 (ZFAS1) in both plasma and platelets of 101 non-small-cell lung cancer (NSCLC) patients. Receiver operating characteristic (ROC) curve was generated to evaluate their diagnostic potential. In addition, epidermal growth factor receptor (EGFR) mutations were detected in DNA and RNA samples of platelets for companion diagnostics. RESULTS: Our results showed that the levels of MAGI2-AS3 and ZFAS1 in both plasma and platelets of NSCLC patients were significantly downregulated than those in healthy controls. A positive correlation of long noncoding RNA expression was observed between platelets and plasma (r=0.738 for MAGI2-AS3, r=0.751 for ZFAS1, respectively). By ROC analysis, we found that molecular interrogation of MAGI2-AS3 and ZFAS1 in TEPs and plasma can offer valuable diagnostic performance for NSCLC patients (area under the ROC curve [AUC] MAGI2-AS3 = 0.853/0.892, and AUC ZFAS1 =0.780/0.744 for diagnosing adenocarcinoma and squamous cell carcinoma cases from controls, respectively). Clinicopathologic characteristic analysis further revealed that MAGI2-AS3 level significantly correlated with tumor-node-metastasis (TNM) stage (p=0.001 in TEPs, p=0.003 in plasma), lymph-node metastasis (p=0.016 in TEPs, p=0.023 in plasma), and distant metastasis (p=0.045 in TEPs, p=0.045 in plasma), while ZFAS1 level was only correlated with TNM stage (p=0.005 in TEPs, p=0.044 in plasma). Furthermore, EGFRvIII RNA existed in both TEPs and plasma, but EGFR intracellular mutations cannot be detected in DNA of TEPs isolated from NSCLC. CONCLUSION: Our data suggested that TEP is a promising source for NSCLC diagnosis and companion diagnostics.

7.
Cell Physiol Biochem ; 46(2): 532-545, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29614511

RESUMEN

BACKGROUND/AIMS: Exosomal circulating long non-coding RNAs (lncRNAs) in blood are emerging as clinically useful and non-invasive biomarkers for tumor diagnosis. However, normal cells can also secrete exosomes, so it is a prerequisite to obtain tumor-derived exosomes for better understanding of their diagnostic impacts in cancer. In this study, a dual-antibody-functionalized immunoaffinity system was established to isolate exosomes and investigate their lncRNAs expression pattern and clinical significance in prostate cancer (PCa). METHODS: A commercially available kit was used to isolate total exosomes, which were then purified by a dual-antibody-functionalized immunoaffinity system. RT-qPCR was performed to detect the expression of exosomal lncRNAs. Receiver operating characteristic (ROC) curves were plotted to assess the diagnostic value. RESULTS: Expression levels of two lncRNAs in tumor-derived exosomes were significantly higher than those in total exosomes. The levels of SAP30L-AS1 were upregulated in benign prostatic hyperplasia (BPH), and SChLAP1 levels were significantly higher in PCa than in BPH and healthy individuals. The area under the ROC curve indicated that SAP30L-AS1 and SChLAP1 had adequate diagnostic value to distinguish PCa from controls. Two lncRNAs separately combined with prostate specific antigen (PSA) possessed a moderate ability for discrimination. SAP30L-AS1 expression level was related to PSA values and tumor invasion. SChLAP1 expression was significantly higher in patients with higher Gleason scores, and was also effective in differentiating between BPH and PCa when the concentration of PSA was in the gray zone. CONCLUSION: The isolation of tumor-derived exosomes by dual-antibody-functionalized immunoaffinity systems and detection of their lncRNAs in plasma may lead to the identification of suitable biomarkers, with potential diagnostic utility.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Exosomas/genética , Neoplasias de la Próstata/diagnóstico , ARN Largo no Codificante/metabolismo , Anciano , Antígenos de Superficie/metabolismo , Área Bajo la Curva , Biomarcadores de Tumor/genética , Línea Celular Tumoral , Proteínas de Unión al ADN/metabolismo , Dispersión Dinámica de Luz , Complejos de Clasificación Endosomal Requeridos para el Transporte/metabolismo , Molécula de Adhesión Celular Epitelial/metabolismo , Exosomas/metabolismo , Glutamato Carboxipeptidasa II/metabolismo , Humanos , Masculino , Microscopía Electrónica de Transmisión , Clasificación del Tumor , Antígeno Prostático Específico/sangre , Hiperplasia Prostática/genética , Hiperplasia Prostática/patología , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/patología , Curva ROC , Tetraspanina 30/metabolismo , Factores de Transcripción/metabolismo , Regulación hacia Arriba
8.
Fertil Steril ; 93(8): 2615-20, 2010 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-19880106

RESUMEN

OBJECTIVE: To investigate the effect of mifepristone on peripheral blood natural killer cell's (pbNK) cytotoxicity and the expression of the inhibitory receptor CD94/NKG2A and the activated receptor NKG2D on pbNK cells. DESIGN: In vitro study. SETTING: University hospital and research laboratory. PATIENT(S): Twenty healthy nonpregnant women. INTERVENTION(S): Detected the cytolytic activity of pbNK to K562 target cells; measured the expression of CD94/NKG2A and NKG2D on pbNK. MAIN OUTCOME MEASURE(S): Cytotoxicity of pbNK was detected by Methyl thiazolyl tetrazolium. The expression of CD94/NKG2A and NKG2D receptor on pbNK cells were detected by flow cytometry. RESULT(S): The NK cell cytotoxicity and the expression of inhibitory receptor CD94/NKG2A during the proliferative phase (81.71 +/- 11.5, 86.6 +/- 9.0) was significantly higher than the secretory phase (60.16 +/- 19.2, 60.15 +/- 31.0). The NK cells cytotoxicity, after being treated with mifepristone and the expression of inhibitory receptor CD94/NKG2A on pbNK cells treated with 200 nmol/L mifepristone, were significantly increased. Mifepristone had no effect on the expression of activating receptor NKG2D. CONCLUSION(S): These data suggest that Mifepristone maybe exert its anti-implantation function by increasing NK cytotoxicity. The increasing NK cytotoxicity of mifepristone is not related to CD94/NKG2A and NKG2D. In the secretory phase down-regulated CD94/NKG2A, NKG2D, and NK cytotoxicity may benefit with embryo implantation.


Asunto(s)
Citotoxicidad Inmunológica/efectos de los fármacos , Células Asesinas Naturales/inmunología , Mifepristona/farmacología , Subfamília C de Receptores Similares a Lectina de Células NK/biosíntesis , Subfamília D de Receptores Similares a Lectina de las Células NK/biosíntesis , Implantación del Embrión , Femenino , Humanos , Ciclo Menstrual/fisiología , Subfamilia K de Receptores Similares a Lectina de Células NK
9.
Gynecol Oncol ; 112(1): 199-204, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19022493

RESUMEN

OBJECTIVE: Decreased number and impaired function of dendritic cells (DCs) have been found in ovarian carcinoma microenvironment. The study was designed to detect if this phenomenon was associated with abnormal DC differentiation influenced by ovarian carcinoma cells. MATERIALS AND METHODS: FLT-3L and SCF were used for expanding DC precursors from CD34+ progenitors. GM-CSF and TNF-alpha were used to induce mature DCs. Supernatants of cultured ovarian carcinoma cell line SKOV3 were added, in order to study their influence on the differentiation and maturation of Lin-CD45RA- DC precursors. Flow cytometry was used to analyze cell subtypes and molecular surface markers. Allogeneic T-cell proliferation assay was used to exam stimulatory activity of DCs. IL-12 secretion was tested by ELISA. RESULTS: Lin-CD45RA- DC precursors cultured with GM-CSF and TNF-alpha generated HLA-DR+CD11C+CD123- myeloid DCs (mDCs) and HLA-DR+CD11C-CD123+ plasmacytoid DCs (pDCs) in vitro. The supernatants from ovarian carcinoma cell line SKOV3 (SKOV3-supernatants) increased pDCs and decreased mDCs compared with pure medium or supernatants of normal ovarian surface epithelial (OSE) cells. There were no significantly different expressions of HLA-DR and CD80 by DCs between with and without SKOV3-supernatants. But DCs treated with SKOV3-supernatants were shown to have impaired immune activity to stimulate proliferation of allogeneic CD3+ T cells and secrete IL-12. CONCLUSION: Ovarian carcinoma cells influence differentiation of Lin-CD45RA- DC precursors into subtypes of mature DCs in vitro. This resulted in fewer mDCs, increased number of pDCs, and impairment of mature DCs immune activity.


Asunto(s)
Diferenciación Celular/inmunología , Células Dendríticas/inmunología , Antígenos Comunes de Leucocito/inmunología , Neoplasias Ováricas/inmunología , Adulto , Células Dendríticas/patología , Femenino , Sangre Fetal/inmunología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Humanos , Activación de Linfocitos , Proteínas de la Membrana/farmacología , Neoplasias Ováricas/patología , Factor de Células Madre/farmacología , Células Madre/inmunología , Células Madre/patología , Linfocitos T/inmunología , Células TH1/inmunología , Células Tumorales Cultivadas , Factor de Necrosis Tumoral alfa/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA